Sebastian Schmid, ESMO 2022: RACE-IT – RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in advanced bladder cancer
Patients with locally advanced bladder cancer have a poor prognosis despite surgical therapy. Prof. Sebastian Schmid (Technical University of Munich, Munich, Germany) joins touchONCOLOGY to discuss the unmet needs in the treatment of locally advanced bladder cancer, and also discusses the feasibility, safety and efficacy of neoadjuvant radio-immunotherapy following radical cystectomy in patients with locally advanced, muscle invasive bladder cancer.
The abstract entitled ‘RACE IT: A prospective, single arm, multicenter, phase II-trial to assess safety and efficacy of preoperative RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in locally advanced urothelial carcinoma of the bladder (AB 65/18) – first results‘ Abstract LBA75, was presented at European Society for Medical Oncology (ESMO) 2022.
Questions:
- What are the unmet needs in the treatment of locally advanced bladder cancer, and what was the rationale for the investigation of preoperative radiation therapy before radical cystectomy combined with immunotherapy in this treatment setting? (0:13)
- What were the aims, design, and study endpoints, and how well were they achieved? (2:30)
- What will be the next steps in the clinical development of this therapeutic approach? (4:21)
Disclosures: Sebastian Schmid receives grant/research support from Bristol-Myers Squibb.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.
